Ulcerative Colitis Market and Forecast Analysis

  • ID: 4238719
  • Report
  • 282 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview:

Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost layer of the intestinal lining. Ulcerative colitis is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Ulcerative colitis is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet. Incidence and prevalence have been increasing over the past two decades in most regions of the world.

It is estimated that in 2015, there were 2.1 million diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015-35, the number of prevalent cases is expected to increase to 2.5 million (16.6% increase).
Note: Product cover images may vary from those shown
2 of 3
1. Treatment: Ulcerative Colitis
Executive Summary
Primary Research Methodology
Patient Segmentation
Country Treatment Trees: Crohn’s Disease
Country Treatment Trees: Ulcerative Colitis
Current Treatment Options
Prescribing Trends: Crohn’s Disease
Prescribing Trends: Ulcerative Colitis
Prescribing Influences
Unmet Needs in Inflammatory Bowel Disease

2. Epidemiology: Ulcerative Colitis
Executive Summary
Disease Background
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Appendix

3. Marketed Drugs: Ulcerative Colitis
Executive Summary
Product Overview
Product profile: Apriso
Product profile: Delzicol/Asacol HD
Product profile: Entyvio
Product profile: Humira
Product profile: Lialda
Product profile: Pentasa
Product profile: Remicade
Product profile: Simponi
Product profile: Uceris

4. Pipeline: Ulcerative Colitis
Executive Summary
Clinical Pipeline Overview
Target Product Profile
Product profile (late stage): LT-02
Product profile (late stage): Xeljanz
Product profile (late stage): etrolizumab

5. Appendix
Appendix: Marketed Drugs: Ulcerative Colitis
Appendix: Pipeline: Ulcerative Colitis

List of Figures:
Figure 1: US Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 2: Japan Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 3: France Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 4: Germany Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 5: Italy Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 6: Spain Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 7: UK Crohn’s disease diagnosed patient population and usage of key drugs, by line of therapy
Figure 8: US ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 9: Japan ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 10: France ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 11: Germany ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 12: Italy ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 13: Spain ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 14: UK ulcerative colitis diagnosed patient population and usage of key drugs, by line of therapy
Figure 15: Mean percentage of Crohn’s disease and ulcerative colitis patients who receive pharmacological therapy, by country
Figure 16: Mean percentage use of Crohn’s disease drug classes in the US, Japan, and five major EU markets, by line of therapy
Figure 17: Mean percentage of drug-treated Crohn’s disease patients treated with monotherapy versus combination therapy, by line of therapy
Figure 18: Mean percentage use of biologics for drug-treated Crohn’s disease patients, by country and line of therapy
Figure 19: Mean percentage use of biologic brands for the treatment of drug-treated Crohn’s disease patients, by line of therapy
Figure 20: Mean compliance rates for drug-treated Crohn’s disease patients, by formulation
Figure 21: Mean percentage use of ulcerative colitis drug classes in the US, Japan, and five major EU markets, by line of therapy
Figure 22: Mean percentage of drug-treated ulcerative colitis patients treated with monotherapy versus combination therapy, by line of therapy
Figure 23: Mean percentage use of biologics for drug-treated ulcerative colitis patients, by country and line of therapy
Figure 24: Mean percentage use of biologic brands for the treatment of drug-treated ulcerative colitis patients, by line of therapy
Figure 25: Mean compliance rates for drug-treated ulcerative colitis patients, by formulation
Figure 26: Mean percentage of Crohn’s disease patients treated by each type of healthcare professional
Figure 27: Mean percentage of ulcerative colitis patients treated by each type of healthcare professional
Figure 28: Top factors that influence the prescribing of biologics and aminosalicylates for inflammatory bowel disease patients
Figure 29: Treatment challenges in Crohn’s disease
Figure 30: Treatment challenges in ulcerative colitis
Figure 31: Trends in diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015-35
Figure 32: Absolute growth of diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015-35
Figure 33: Male diagnosed prevalent ulcerative colitis cases in each age group in the US, Japan, and five major EU markets, by country, 2015
Figure 34: Female diagnosed prevalent ulcerative colitis cases in each age group in the US, Japan, and five major EU markets, by country, 2015
Figure 35: Apriso for ulcerative colitis - SWOT analysis
Figure 36: Drug assessment of Apriso in ulcerative colitis
Figure 37: Drug assessment of Apriso in ulcerative colitis
Figure 38: Delzicol and Asacol HD for ulcerative colitis - SWOT analysis
Figure 39: Drug assessment of Delzicol (Asacol)/Asacol HD in ulcerative colitis
Figure 40: Drug assessment of Delzicol (Asacol)/Asacol HD in ulcerative colitis
Figure 41: Entyvio for ulcerative colitis - SWOT analysis
Figure 42: Drug assessment of Entyvio in ulcerative colitis
Figure 43: Drug assessment of Entyvio in ulcerative colitis
Figure 44: Humira for ulcerative colitis - SWOT analysis
Figure 45: Drug assessment of Humira in ulcerative colitis
Figure 46: Drug assessment of Humira in ulcerative colitis
Figure 47: Lialda for ulcerative colitis - SWOT analysis
Figure 48: Drug assessment of Lialda in ulcerative colitis
Figure 49: Drug assessment of Lialda in ulcerative colitis
Figure 50: Pentasa for ulcerative colitis - SWOT analysis
Figure 51: Drug assessment of Pentasa in ulcerative colitis
Figure 52: Drug assessment of Pentasa in ulcerative colitis
Figure 53: Remicade for ulcerative colitis - SWOT analysis
Figure 54: Drug assessment of Remicade in ulcerative colitis
Figure 55: Drug assessment of Remicade in ulcerative colitis
Figure 56: Simponi for ulcerative colitis - SWOT analysis
Figure 57: Drug assessment of Simponi in ulcerative colitis
Figure 58: Drug assessment of Simponi in ulcerative colitis
Figure 59: Uceris SWOT analysis in ulcerative colitis
Figure 60: Drug assessment of Uceris in ulcerative colitis
Figure 61: Drug assessment of Uceris in ulcerative colitis

List of Tables:
Figure 62: LT-02 for ulcerative colitis - SWOT analysis
Figure 63: Drug assessment of LT-02 in ulcerative colitis
Figure 64: Drug assessment of LT-02 in ulcerative colitis
Figure 65: Results from Phase II trial of Xeljanz in ulcerative colitis
Figure 66: Xeljanz for ulcerative colitis - SWOT analysis
Figure 67: Drug assessment of Xeljanz in ulcerative colitis
Figure 68: Drug assessment of Xeljanz in ulcerative colitis
Figure 69: Etrolizumab for ulcerative colitis - SWOT analysis
Figure 70: Drug assessment of etrolizumab in ulcerative colitis
Figure 71: Drug assessment of etrolizumab in ulcerative colitis
Table 1: Gastroenterologists surveyed for the inflammatory bowel disease primary research study
Table 2: Definition of mild, moderate, and severe Crohn’s disease
Table 3: Definition of mild, moderate, and severe ulcerative colitis
Table 4: Drug classes used in the treatment of inflammatory bowel disease
Table 5: Treatment guidelines: initial treatment for active Crohn’s disease, by severity
Table 6: Treatment guidelines: maintenance of medically induced remission of Crohn’s disease and other therapy recommendations
Table 7: Treatment guidelines: initial treatment for active ulcerative colitis, by severity
Table 8: Treatment guidelines: maintenance of medically induced remission of ulcerative colitis and other therapy recommendations
Table 9: Mean percentage of drug-treated Crohn’s disease patients treated with monotherapy versus combination therapy, by line of therapy and country
Table 10: Mean percentage of drug-treated Crohn’s disease patients receiving each biologic, by country and line of therapy
Table 11: Mean percentage of drug-treated ulcerative colitis patients treated with monotherapy versus combination therapy, by line of therapy and country
Table 12: Mean percentage of drug-treated ulcerative colitis patients receiving each biologic, by country and line of therapy
Table 13: Factors influencing prescription of biologics and aminosalicylates for inflammatory bowel disease, by country
Table 14: Mean ranking given to each clinical unmet need in the treatment of Crohn’s disease, by country
Table 15: Mean ranking given to each clinical unmet need in the treatment of ulcerative colitis, by country
Table 16: Inflammatory bowel disease risk factors
Table 17: Sources used for ulcerative colitis analysis in the US, Japan, and five major EU markets
Table 18: Notable sources not used for ulcerative colitis analysis in the US, Japan, and five major EU markets
Table 19: Summary of ulcerative colitis data processing in the US, Japan, and five major EU markets
Table 20: Diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015-35
Table 21: Age- and gender-specific diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets, by country, 2015
Table 22: Phenotypic distribution of ulcerative colitis at diagnosis, by Montreal classification and country, 2015
Table 23: Key marketed drugs for ulcerative colitis
Table 24: Apriso drug profile
Table 25: Overview of pivotal trial data for Apriso in ulcerative colitis
Table 26: Delzicol/Asacol HD drug profile
Table 27: Overview of pivotal trial data for Asacol and Asacol HD in ulcerative colitis
Table 28: Entyvio drug profile
Table 29: Overview of pivotal trial data for Entyvio in ulcerative colitis
Table 30: Overview of Entyvio ulcerative colitis trial in Japan
Table 31: Ongoing long-term clinical trial of Entyvio in Crohn’s disease and ulcerative colitis
Table 32: Humira drug profile
Table 33: Pivotal trial data that led to Humira’s approvals for Crohn’s disease and ulcerative colitis
Table 34: Ongoing clinical trial of Humira in ulcerative colitis
Table 35: Lialda drug profile
Table 36: Overview of pivotal trial data for Lialda in ulcerative colitis
Table 37: Other key clinical trial data for Lialda in ulcerative colitis
Table 38: Ongoing clinical trials of Lialda in ulcerative colitis
Table 39: Pentasa drug profile
Table 40: Overview of pivotal trial data for Pentasa in ulcerative colitis
Table 41: Remicade drug profile
Table 42: Overview of pivotal trial data for Remicade in ulcerative colitis
Table 43: Simponi drug profile
Table 44: Overview of pivotal trial data for Simponi in ulcerative colitis
Table 45: Overview of Simponi Phase III trial for ulcerative colitis in Japanese patients
Table 46: Uceris drug profile
Table 47: Overview of pivotal trial data for Uceris in ulcerative colitis
Table 48: Phase III data for Uceris/mesalamine combination therapy in ulcerative colitis
Table 49: Ongoing Phase III trial of Uceris in Japanese ulcerative colitis patients
Table 50: Phase III pipeline candidates under development for ulcerative colitis
Table 51: Remicade drug profile
Table 52: Ability of comparator therapy Remicade to meet unmet needs in ulcerative colitis
Table 53: LT-02 drug profile
Table 54: Ongoing pivotal trials of LT-02 in ulcerative colitis
Table 55: Results of the Phase II trial of LT-02 in ulcerative colitis
Table 56: Xeljanz drug profile
Table 57: Ongoing pivotal trials of Xeljanz in ulcerative colitis
Table 58: Etrolizumab drug profile
Table 59: Ongoing pivotal trials of etrolizumab in ulcerative colitis
Table 60: Results of the Phase II EUCALYPTUS trial of etrolizumab in ulcerative colitis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll